Panacea Technical Articles

Drug/device Combinations: Device vigilance or Pharmacovigilance?
13.10.2023 | Article

Dr Liezl Schonken, who is a Safety Physician at Panacea, has written an article about drug/device combination products and whether device vigilance or pharmacovigilance applies.

Read More
The Safety of Herbal Medicinal Products
03.10.2023 | Article

Sevda Hubanova Yoztyurk, who is a Pharmacovigilance Scientist & QPPV Office Co-ordinator at Panacea, has written an article about the safety of herbal medicinal products.

Read More
From paper to data – the evolution of the application form
11.09.2023 | Article

Lauren Morley, a Senior Regulatory Affairs Specialist at Panacea, looks at the evolution of application forms, from paper to electronic.

Read More
My Journey in Pharmacovigilance
01.09.2023 | Article

Maria Hull discusses her time at Panacea and her experiences in pharmacovigilance.

Read More
My journey to becoming an EU QPPV at Panacea
11.08.2023 | Article

Francisco Ferreira discusses his pharmacovigilance journey to becoming an EU QPPV at Panacea.

Read More
Implementation of Pharmacogenomics to Prevent Adverse Drug Reactions
27.10.2021 | Article

Liezl Schonken, a Safety Physician at Panacea, discusses pharmacogenomics and how it may be implemented to prevent adverse drug reactions.

Read More
Working as a QPPV at Panacea
18.10.2021 | Article

Michelle Patton discusses her experiences of being an EU QPPV at Panacea.

Read More
Developmental Risk Management Plans in Pharmacovigilance
11.10.2021 | Article

Martika Taylor, a Senior Safety Scientist at Panacea, looks at the use of Developmental Risk Management Plans (DRMPs) in Pharmacovigilance.

Read More
Biological & Biosimilar Medicines – Pharmacovigilance Particularities from a Safety Physician’s Perspective in the EU (Part Two)
04.10.2021 | Article

Part Two looks at PV specifics and also Quality, Non-clinical and Clinical issues and their interconnection with safety.

Read More
Biological & Biosimilar Medicines – Pharmacovigilance Particularities from a Safety Physician’s Perspective in the EU (Part One)
27.09.2021 | Article

Ludmila Curi, a Panacea EU QPPV and Safety Physician, looks at the PV considerations for Biological and Biosimilar medicines in the EU.

Read More